Vimarsana
Biggest News Aggregation in the World

Page 20 - Herlev News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Herlev. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Herlev Today - Breaking & Trending Today

Head to Head Survey: Cidara Therapeutics (NASDAQ:CDTX) versus Evaxion Biotech A/S (NASDAQ:EVAX) - Vimarsana News

Head to Head Survey: Cidara Therapeutics (NASDAQ:CDTX) versus Evaxion Biotech A/S (NASDAQ:EVAX)

Cidara Therapeutics (NASDAQ:CDTX – Get Rating) and Evaxion Biotech A/S (NASDAQ:EVAX – Get Rating) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, profitability, institutional ownership and valuation. Institutional & Insider Ownership 46.3% of Cidara Therapeutics […]

Nitrates and Erectile Dysfunction Meds? Increasingly Common, Mostly Benign - Vimarsana News

Nitrates and Erectile Dysfunction Meds? Increasingly Common, Mostly Benign

The authors say doctors who are safely prescribing both may be doing a good job of explaining how to avoid serious interactions.

Source: tctmd.com
Coprescribing PDE5 Inhibitors and Nitrates May Be Safe - Vimarsana News

Coprescribing PDE5 Inhibitors and Nitrates May Be Safe

There is a scarcity of real-world data showing that using both types of drugs together increases these risks.

PDE5 Inhibitors Prescribed for Men on Oral Nitrates for IHD - Vimarsana News

PDE5 Inhibitors Prescribed for Men on Oral Nitrates for IHD

MONDAY, April 18, 2022 (HealthDay News) — For men prescribed nitrates for ischemic heart disease (IHD), new prescriptions of phosphodiesterase type 5 (PDE5) inhibitors increased from 2000 to 2018, but an association between coprescription and adverse cardiovascular events was not observed, according to a study published online April 19 in the Annals of Internal Medicine. […]

14-Yr-Old Nicholas Castella Crushes 1:50.44 200 Free In Denmark - Vimarsana News

14-Yr-Old Nicholas Castella Crushes 1:50.44 200 Free In Denmark

Just when you think the men's 200m free was competitive enough one the senior level, the juniors upcoming are crushing some ridiculous times as well.